Doubts about the efficacy of Janssen return: a booster dose is considered

Doubts about the efficacy of the Janssen vaccine against variants of the virus return. Thus, the experts of the Vaccine Report, have proposed to the Public Health Commission that the possibility of administering a booster dose be assessed.

The beginning of Janssen’s doubts

The first doubts about the Janssen vaccine began to arise with the advance of the Delta variant of the coronavirus. Thus, several US experts began to recommend and inject

“There is no question that people who get the J&J vaccine are less protected against disease” than those who get two doses of the other shots, Dr. Michael Lin, a Stanford professor, told Reuters. In the same vein, the agency collects, vaccine expert Peter Hotez, a doctor at Baylor College of Medicine, said in a tweet that adding a second dose of Janssen or one of the mRNA vaccines could provide broader protection, but we need data and guidance from CDC and FDA.

The pharmaceutical company that developed the vaccine solved this crisis by announcing that its drug was effective and highly neutralizing against Delta. “The recently announced studies strengthen the ability of Johnson & Johnson’s COVID-19 vaccine to help protect the health of people around the world,” said Paul Stoffels, Johnson & Johnson’s Executive Committee Vice Chairman and Chief Scientific Officer. “We believe that our vaccine offers long-lasting protection against COVID-19 and elicits neutralizing activity against the Delta variant,” he adds.

High percentage of vaccinated with Janssen in the CUs

A recent study carried out by the Lyon and Grenoble pharmacovigilance centers, and published by the French National Drug Safety Agency, has once again raised doubts. Specifically, it has reflected in its conclusions the presence in the ICU of a high number of vaccinated with Janssen.

“A potential signal has been highlighted in the face of a large number of cases of vaccine failure with Janssen, with patients in intensive care or who have died from COVID-19, most of them with serious risk comorbidities,” concludes the article published this Tuesday.